Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes.

Drug metabolism and pharmacokinetics - 1 Jan 2013

Ando Yukie, Shimada Hideaki, Matsumoto Nozomi, Hirota Takeshi, Oribe Motohiro, Otsuka Eiji, Ishii Kohji, Morimoto Takuya, Ohashi Kyoichi, Ieiri Ichiro

Abstract excerpt

The aims of the present study were to define inter-individual differences in response to methotrexate (MTX) through MTX polyglutamate (MTX-PG) levels in red blood cells (RBC) and MTX-related gene polymorphisms. A total of 145 rheumatoid arthritis patients were recruited. MTX-PG1-5 concentrations in RBC were measured, and 11 single nucleotide polymorphisms, all in MTX-related genes involved in the folate pathway,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Arthritis, Rheumatoid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Erythrocytes

Share to RFC1 gene

Share to Methotrexate

Share to Polymorphism, Single Nucleotide

Share to Reduced Folate Carrier Protein

Source

Identifiers

PMID: 23545592
DOI: 10.2133/dmpk.dmpk-12-rg-128

Genes

RFC1
CRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes.PMID 23545592Read ↗

MTX pathway gene variants, erythrocyte methotrexate polyglutamates, and treatment outcomes in rheumatoid arthritis.Semantic proximity Read ↗

Effect of Genetic Polymorphisms in the Folate Pathway on Methotrexate Therapy in Rheumatic DiseasesSemantic proximity Read ↗

Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexateSemantic proximity Read ↗

Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients.Semantic proximity Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.Semantic proximity Read ↗

The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.Semantic proximity Read ↗

The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.Semantic proximity Read ↗

A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.Semantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.